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Pulmonary alveolar proteinosis (PAP) is a term defining an ultra-rare group of disorders characterised by a
perturbation in surfactant homeostasis, resulting in its accumulation within airspaces and impaired gas transfer. In
this report we provide data from a cohort of PAP patients (n = 81) followed for more than two decades at the San
Matteo University Hospital of Pavia, Italy. In agreement with other large series in PAP individuals, 90% of the study
subjects were affected by autoimmune/idiopathic PAP, while the remaining subjects were divided as follow:
congenital 1%, secondary 4% and PAP-like 5%. The disease affected males and females with a ratio of 2:1 and
approximately one third of PAP patients were lifelong nonsmokers. Occupational exposure was reported in 35% of
subjects in this series. With reference to the PAP clinical course, in 29 patients (7% with spontaneous remission)
disease severity did not necessitate whole lung lavage (WLL) in the long-term follow up. On the other hand, 44
PAP patients underwent therapeutic WLL: in 31 subjects a single WLL was sufficient to provide long term, durable
benefit, whereas 13 patients required multiple WLLs. The intra-patient mean interval between two consecutive
WLLs was 15.7 ± 13.6 months. When baseline data among never lavaged and PAP patients lavaged at least once
were compared, the need for lavage was significantly associated with serum biomarkers (CEA, Cyfra, LDH), lung
function parameters forced vital capacity (FVC), and lung diffusing capacity (Dlco). We conclude that patient cohorts
with an ultra-rare disease, such as PAP, referred to a single reference center, can provide useful information on the
natural history and clinical course of the disease.Background
Pulmonary alveolar proteinosis (PAP) is a syndrome
characterized by the accumulation of surfactant within
alveolar macrophages and alveoli, which impairs pul-
monary gas transfer and results in clinical severity ran-
ging from an asymptomatic clinical presentation to
respiratory failure and death [1]. The prevalence of auto-
immune (previously referred to as idiopathic) PAP is
0.1/100,000 , and accounts for about 90% of PAP cases
[2,3]. According to such figures, PAP is considered an
ultra-rare disorder. In spite of major advances achieved
in the late ‘90s when the group of Koh Nakata first
described the presence of autoantibodies neutralizing
GM-CSF in serum and lung tissue of patients with* Correspondence: m.luisetti@smatteo.pv.it
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reproduction in any medium, provided the oridiopathic PAP [4,5], several specific treatments have
been attempted or postulated [6], but the standard of
care is still the whole lung lavage (WLL), eventually
modified after the original description by Ramirez in
1963 [7]. As a result, nowadays PAP is no longer consid-
ered a potentially lethal disorder.
Descriptions of large series of PAP patients in the li-
terature over the years have greatly extended the know-
ledge on the natural history of the disorder. Following
the meta-analysis of 410 cases by Seymour and Presneill
[8], who reviewed all PAP cases available in the litera-
ture, including 34 PAP cases followed at the Mayo Clinic
Center in Rochester [9], other large multicenter series
were published in Japan in 2008 (248 cases) [10] and
China (241 cases) [11]. In 2011, Bonella and associates
described the characteristics of a cohort of 70 PAP pa-
tients followed at a single center in Essen, Germany [12].
In this communication we report on a cohort of 81 PAPLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Matteo University Hospital of Pavia, Italy. It should be
emphasized that the series of patients described in a sin-
gle reference center, although less relevant than large
meta-analysis or multicenter series, has however the ad-
vantage of including detailed experience accumulated
over several years (decades, as in our case).
This is of special relevance as many treatment aspects,
such as WLL for PAP, have not been investigated in depth.
In this report, we have focused on two aims : first, the
description of the clinical characteristics of the disease
at presentation in our series of PAP patients; secondly,
to analyse some baseline functional and biochemical
parameters in function of the long term follow up of pa-
tients, especially with respect to the need for WLL. The
latter has not been covered in the literature so far.
Methods
Patients’ diagnosis and assessment
Progressive recruitment of patients with surfactant asso-
ciated disorders started after the first WLL performed in
1989. Diagnostic tools were the presence of “crazy paving
pattern” at the high resolution computed tomography
scan images of the thorax and the presence of macros-
copic milky fluid and/or the presence of amorphous, eo-
sinophilic, PAS positive material, as well as lipid laden
macrophages on bronchoalveolar lavage analysis [1].
Determination of serum level of autoantibodies anti-
GM-CSF (GMAbs) was performed in the Laboratory of
the Rare Lung Disease Consortium at the Cincinnati
Children’s Hospital Medical Center beginning 2004 [4,5].
Lung biopsies (surgical or transbronchial), if available,
were reviewed and evaluated according to current criteria
for diagnosis of PAP [13]. Diagnosis of the kind of surfac-
tant associated disorder was performed according to the
classification: primary (also referred to as idiopathic or
autoimmune) PAP, secondary PAP, hereditary PAP, and
PAP-like disorders [1]. Pulmonary functional assessment
and WLL were performed according to Beccaria and co-
workers [14]. The indication for WLL were as follows :
a) persistent or progressive respiratory failure; b) no res-
piratory failure, but drop by 5 or more percentage points
of O2 saturation on treadmill exercise (modified Bruce
protocol) determined by pulse oxymetry [14]. Serum mea-
surements described in the text (LDH, Cyfra 21-1, CEA,
NSE) were performed in the clinical chemistry facilities
according to internal standard operative procedures.
The investigation was conducted in compliance with
the Helsinki declaration and approved by the Ethics
Committee of the San Matteo Hospital Foundation.
Statistical analysis
The Shapiro-Wilk test was used to test the normal
distribution of quantitative variables. When quantitativevariables were normally distributed, the results were
expressed as mean values and SD, otherwise median and
interquartile range (IQR; 25th -75th percentile) were
reported. The one-way ANOVA (or non parametric
Kruskall-Wallis for skewed distributions), with Bonferroni
correction for comparisons between two groups, was
employed to investigate differences among the three study
groups (PAP patients never lavaged, lavaged once or more
times). Qualitative variables were summarized as counts
and percentages and the Chi-square (χ2) test were used to
compare gender among study groups. P < 0.05 was consi-
dered statistically significant and all tests were two-sided.
Data analysis was performed with the STATA statistical
package (release 11,1, 2010, Stata Corporation, College
Station, Texas, USA).
Results
Beginning January 1989, we progressively evaluated sub-
jects admitted to our center with surfactant associated
disorders (Figure 1). As of June 2011, eighty-one patients
had been enrolled and classified according to Luisetti &
Trapnell [1] (Tables 1 and 2). In order to keep the study
group as homogeneous as possible, in this paper we
focused on primary PAP (idiopathic and autoimmune)
patients only, herein collectively referred to as PAP pa-
tients. Demographic, clinical, and assessment features of
the 73 PAP patients are reported in Table 2. The male:
female ratio was 2:1. With reference to environmental
factors, the majority of PAP patients in our series were
smokers (either current or former), but a significant
fraction of subjects (33%) never smoked. Among those
reporting professional exposure, 19 out of 26 were ex-
posed to inorganic dusts (silica, cement), 1 to organic
dusts, 2 to combustion products, 1 to chemicals (photo-
graphic fixer) and 3 to pesticides.
Among symptoms reported at the time of diagnosis,
the majority of PAP patients complained about dyspnea
(67%) and cough (31%); only one reported sputum
production.
Among the four diagnostic tools used, 74% of patients
were assessed by high resolution (HR) CT scan, followed
by lung biopsy (surgical or transbronchial), and bron-
choalveolar lavage (BAL). Interestingly, the introduction
of GMAbs measurement in 2004 did not substantially
change the diagnostic attitude: before 2004, lung biopsy
was performed in 60.6% of PAP patients, and thereafter
the percentage dropped only to 52.5%. Twelve patients
were affected by a respiratory infection at the moment
of diagnosis. As far as the lung function data are
concerned, our results are in line with the previous func-
tional report on our initial PAP series [14], with relevant
impairment particularly in DLco and Δ(A-a)O2.
The mean value of all available biomarkers were above






















Figure 1 Progressive enrollment of subjects with surfactant associated disorders in the Pavia center.
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http://www.ojrd.com/content/8/1/40became available in 2004, confirmed the autoimmune
nature in 100% of PAP cases diagnosed since that year.
Finally, about two thirds of the PAP patients were classi-
fied as Disease Severity Score (DSS) 2 or 3 [10,15,16].
All patients from our cohort were evaluated for WLL,
the current standard of care for PAP.
According to above described criteria, 44 out of 73
PAP patients (60%) were submitted to 1 or multiple
WLLs, whereas 29 patients (40%) did not require WLL





Idiopathic + autoimmune1 73 90
Hereditary2 1 1









1 We began to measure serum GMAb level in 2004, thus for accuracy in this
group we included patients with idiopathic PAP (n = 42, those diagnosed
before 2004) and patients with autoimmune PAP (n = 31, those diagnosed after
2004), although currently they are considered synonymous. 2 This subject was
affected by PAP due to a GM-CSF receptor αchain mutation [17]. 3 This group
includes two subjects with PAP secondary to hematologic disorders (1 chronic
myeloid leukemia and 1 myelodysplastic syndrome) and 1 subject affected by
lysinuric protein intolerance (the latter’s case history has already been
reported) [18,19]. 4 This group includes four subjects with a mutation in the
ABCA3 gene (manuscript in preparation).Baseline data between never lavaged PAP patients were
compared with those who had undergone one or re-
peated lavages and are reported in Table 3. The analysis
of the data available from 28 out of 44 lavaged PAP pa-
tients are presented; in the remaining 16 PAP patients
the data set was incomplete, mostly because they were
referred to our center or directly to the Intensive Care
Unit in such a severe that a complete pre-lavage func-
tional assessment was not possible. Interestingly, this
analysis thus refers to a relatively mildly affected subset
of PAP patients, in which the decision to perform WLL
was sometimes more difficult. According to these data,
the best predictors for the need to perform WLL were
biomarkers (CEA, Cyfra, LDH) and the functional pa-
rameters diffusing capacity (DLco) and FVC. Interest-
ingly, the disease severity score (DSS), combining
presence or absence of symptoms with level of PaO2,
was not significantly different between not lavaged and
lavaged PAP patients. Consistently, also the Δ(A-a)O2
and PaO2 did not significantly differ. No baseline pa-
rameter was able to discriminate PAP patients requiring
in their follow up 1 single WLL from those eventually
requiring more than 1 WLLs.
Discussion
In this study, the enrollment characteristics of the largest
series of PAP patients followed in a single, reference cen-
ter are described. In spite of the retrospective nature of
the study, the series of PAP patients was large enough to
evaluate some selected parameters as indicators of WLL.
In a previous study [14] we presented baseline data from
an initial cohort and assessed the long-term efficacy of
WLL as the current standard of care for PAP [5]. In that
study, a total of 21 PAP patients were evaluated, of whom
15 agreed to participate in a long-term follow up after
WLL. In the present paper, after 11 years of progressive
recruitment, we present data from a total of 73 patients
Table 2 Characteristics and assessment of the PAP cohort
n. % m ± sd
73














sputum production 1 1
Asymptomatic 4 5
Diagnostic procedures3 69




Infection at enrollment4 14 19
Lung Function5
FVC 57 75.50 ± 21.1 (% predicted)
FEV1 57 77.77 ± 18.49 (% predicted)
TLC 57 75.38 ± 14.77 (% predicted)
DLCO 57 51.83 ±17.90 (% predicted)
PaO2 57 64.46 ± 14.17 (mm Hg)
ΔA-aO2 57 41.44 ± 16.25 (mm Hg)
Exercise Sat.O2 57 -4.27% ± 1.93
Biomarkers 6
Cyfra 21-1 26 12.8 ± 14.6 (ng/mL) (nv: 0.0-3.3)
CEA 27 13.4 ± 13.4 (ng/mL) (nv: 0.0-5.0)
NSE 23 20.04 ± 6.9 (ng/mL) (nv: 0.0-15.0)
LDH 57 550.3 ± 248 (U/L) (nv: 230-460)
GMAbs 31 184.1 ± 175 (μg/ml) (nv < 3)








1Subjects exposed for work-related reasons to dust, smoke or gas of organic
or inorganic origin. 2Patients may report more than one symptom.3No data
available in 4/73 pts. More than one diagnostic tool was applied in 58 PAP
patients (84%). Measurement of GMAbs began in 2004.4These include
respiratory infections in 12 patients (4 Staph.aureus, 3 Str.pneumoniae, 1 Pn.
jiroveci, 1 Kleb.pneumoniae, 1 Nocardia ast., 1 Serratia Marcesc., 1 Candida Alb)
and 2 isolates of H.pilorii from gastric biopsy. 5Abbreviation legends: FVC:
forced vital capacitiy; FEV1: forced expiratory flow in the first second; TLC: total
lung capacity; DLCO: diffusing lung capacity for carbon monoxide; PaO2:
arterial oxygen tension; ΔA-aO2: alveolar to arterial oxygen tension difference;
%predicted: percentage of the predicted value; nv: normal value.
6Abbreviation legends: Cyfra 21-1: cytokeratin 19 fragment 21-1; CEA:
carcinoembrionic antigen; NSE: neuron specific enolase; LDH: lactate
dehydrogenase. 7 DSS: disease severity score [10].
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of our findings, we discuss the enrollment data in com-
parison, when possible, with those of other large series of
PAP patients [8,10-12] (Table 4). This table includes data
from a total of 1,050 PAP patients, the largest group of
PAP patients ever analyzed. We confirm that PAP is a dis-
ease affecting young adults (mean age ranging from 39 to
51 years), mostly males: the male:female ratio was the
highest in the Seymour worldwide series [8] and the low-













Figure 2 PAP patients divided according to the number of
WLLs received. Twenty-nine patients were never submitted to WLL,
whereas 44 were lavaged at least once. PAP patients requiring an
additional WLL within 30 days from the previous one (3/31), were
considered to be submitted to a single WLL. In patients requiring
multiple WLLs, the mean (± SD) interval between two consecutive
WLLs was 15.7 (±13.7) months.
Table 3 Analysis of baseline pulmonary function data between PAP patients never lavaged and lavaged once or more
times
No WLL (n = 19) 1 WLL (n = 18) >1 WLL (n = 10) p value
CEA median (iqr) 5 (3-8) 13 (8-30) 8.5 (7-12) 0.04180191
Cyfra median (iqr) 4.5 (2-5) 13 (9-16) 5 (2-32.5) 0.02753042
LDH mean (sd) 368.67 (109.78) 622.14 (263.26) 536.2 (166.89) 0.01267933
NSE mean (sd) 19.2 (5.72) 20.6 (6.22) 22 (4) 0.8022085
DSS mean (sd) 2.67 (1.22) 3.06 (1.25) 3.57 (.98) 0.3353056
FEV1 (%Pred) mean (sd) 82.82 (14.79) 75.8 (22.63) 65.88 (12.23) 0.1087558
FEV1/Vc (%Pred) mean (sd) 100.43 (5.17) 105.47 (8.71) 103 (8.25) 0.1804334
FVC (%Pred) mean (sd) 83.89 (13.16) 73.17 (21.83) 61.57 (9.03) 0.01450884
PaCo2 (mmHg) mean (sd) 35.15 (3.4) 33.91 (3.9) 33.93 (4.07) 0.6664365
PaO2 (mmHg) mean (sd) 70.95 (13.25) 62.64 (13.01) 59.2 (8.96) 0.1019723
TLC (%pred) mean (sd) 79.43 (8.15) 74.47 (17.92) 65.43 (14.03) 0.115102
DLco (%pred) mean (sd) 61.89 (19.27) 45.95 (14.29) 42.63 (11.17) 0.00381985
DLco (mmolkpas) mean (sd) 6.52 (3.41) 4.08 (1.61) 3.84 (1.06) 0.00875156
ΔA-aO2 mean (sd) 34.85 (16.28) 44.84 (16.43) 48.14 (8.76) 0.1299473
1no WLl vs 1 WLL: p = 0.006057; 2no WLl vs 1 WLL: p = 0.005202; 3no WLl vs 1 WLL: p = 0.011; 4no WLl vs >1 WLL: p = 0.016; 5no WLl vs 1 WLL: p = 0.010, no WLl
vs >1 WLL: p = 0.021; 6no WLl vs 1 WLL: p = 0.015, no WLl vs >1 WLL: p = 0.05.
Campo et al. Orphanet Journal of Rare Diseases 2013, 8:40 Page 5 of 7
http://www.ojrd.com/content/8/1/40was a great agreement on the prevalence of secondary
PAP cases : 90% of PAP cases are primary (or auto-
immune) in the Japanese, Germans, and Italians, with
a rate of 10% or less for secondary PAP [17-19]. Moreover,
in all except the Chinese series [11] (which was not evalu-
ated) the rate of spontaneous remitters is very homoge-
neous, ranging from 5 to 7% total cases, a much lower
rate than that proposed in the past (about 30%) [9]. Data
from the Italian PAP cohort follow the other series’ smok-
ing habits: although a majority of PAP patients are smokers
(current or former) a significant portion of PAP patients







39 (30-46) 51 (41-58)
Ratio Male/Female 2.6 2.0
Primary PAP (%) n.a. 90
Secondary PAP (%) n.a. 10
Time to diagnosis
(months)








Dust exposure (%) n.a. 26
Whole lung lavage 54% n.a.series to 43% in the Japanese cohort. Professional exposure
was another feature with a possible impact on PAP patho-
genesis [10]. It occurs at a variable rate: in our series it is
similar to that of the Japanese (32 and 26%, respectively)
and at a lower rate than in German series (54%). A marked
difference among series was the rate of asymptomatic PAP
cases at diagnosis: in our hands they account for 5% of the
entire series, whereas, in the Japanese series they account
for approximately 30% [10]. Another interesting finding,
restricted to our series, is the elevation of cancer bio-
markers (CEA, Cyfra 21-1, NSE) (Table 2). Although some
papers have previously reported such an elevation [20,21],Xu (2009) [11]
(n = 241)
Bonella (2010)
[12] (n = 70)
Campo (2012) [this
paper] (n = 81)
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and in longitudinal perspective, but this should be the aim
of a future analysis.
As emphasized above, WLL is the current standard of
care for autoimmune and other forms of PAP [6]. As
shown in Table 4, the procedure was adopted in 54% of
PAP patients in the Seymour study, data are in line with
the Seymour and Chinese series, with 54% of PAP pa-
tients submitted to WLL. Twenty-nine out of our 73 pa-
tients were never submitted to WLL during their follow
up. No patient refused the treatment; the decision was
based on medical evaluation, since the degree of lung in-
volvement did not alter the lung function. In other
words, in these patients the WLL, an invasive and po-
tentially harmful procedure, was considered unnecessary.
Of the 44 patients in our series submitted to WLL, in 31
(70%), a single WLL was sufficient to ensure long-term,
durable benefit in lung function. Such a benefit, of
course, does not exclude disease relapse, but not to such
a severe degree requiring an additional WLL. It is note-
worthy, that among the 31 PAP patients lavaged only
once, included are 3 PAP patients who required two
consecutive WLLs within one month, as no substantial
improvement after the first lavage was achieved. In this
case, the 2 consecutive WLLs were considered as one.
These data confirm that in 2/3 of PAP patients, a single
WLL is sufficient to induce long-term, and in some
cases definitive, stable, improvement of lung function. In
13 PAP patients, multiple WLLs were necessary to
maintain satisfactory lung function, and only in 5 out of
13, were more than 2 WLLs necessary. The mean inter-
val between two WLLs in the same PAP patient was
15.7 ± 13.6 months.
Although performed in several centers, the WLL pro-
cedure still lacks standardization. Indications when to per-
form WLL remain one of the undefined aspects, since
precise guidelines on patients who will benefit from WLL
are still lacking. The huge difference among centers
concerning the percentage of PAP patients submitted to
WLL reported in Table 4 is a clear example of lack of pre-
cise guidelines. Respiratory failure, particularly when se-
vere enough to require mechanical ventilation, does not
need any decisional discussion, whereas latent respiratory
failure, triggered by exercise only, with radiology imaging
stable over a prolonged period of time, raises concerns on
the decision to lavage. Although our data were unable to
provide a definitive answer to this question, we endeav-
ored to compare the baseline value of never lavaged PAP
patients with those of PAP patients submitted to WLL
(Table 3). Our aim was to evaluate some selected and
available parameters with the Disease Severity Score
(DSS), a combination of presence and absence of symp-
toms and degree of PaO2 [10,15], in the decision making
whether or not to submit a patient to WLL. DSS wasunable to discriminate PAP not requiring WLL from those
mildly affected, with latent respiratory failure, whereas
other parameters, such as the cancer biomarkers, FVC
and DLco were significantly different in the PAP two pop-
ulations. Consistently with the DSS behavior, PaO2 and
Δ(A-a)O2 did not differ significantly. We therefore con-
clude that DSS is not an useful tool for decision making
with respect to WLL, and we hypothesize that the score
should be integrated with other parameters, such as those
herein evaluated, and perhaps with a CT scoring system,
to generate a composite marker. Hopefully such score
could more useful to help in the decision for WLL and in
the evaluation of the effectiveness of interventional trials.
None of the tested markers was able to discriminate the
PAP patients lavaged once from those requiring more
than one single WLL.
A major limitation of the study is its retrospective na-
ture, in turn affecting in some cases quality and avail-
ability of the collected data. This is however balanced by
the remarkable sample size, taking into consideration
the extreme rarity of PAP.
As already emphasized by Bonella and associates [12]
we would like to reinforce the importance of gathering
patients affected by this rare condition in a single refer-
ence center, where optimal care can be provided. This is
especially the case with WLL, a procedure that has been
performed for 50 years, first described in 1963 [7], but
as yet not standardized. Moreover, the WLL procedure
is seldom described in detail in the scientific literature.
We believe that efforts should be increased to create an
operating network among centers performing WLL ei-
ther in adults or pediatric PAP patients, to share experi-
ence and develop common protocols to answer the
many unanswered questions about WLL in PAP.
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